InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Browse the detailed record of transactions filed by Luly Jay R., Chairman & CEO. Director active across 1 companies, notably Enanta Pharmaceuticals INC. Aggregated, 9 disclosures have been logged. Total volume traded: €451k. The latest transaction was filed on 14 February 2022 — Attribution. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations9 total
01,627 shares0
Common Stock
SEC:0001062993-22-004510:0·
€103,37810,063 shares@ €10.27310.027% mcap21.6% of flow
Common Stock
SEC:0001062993-22-001104·
€103,37810,063 shares@ €10.27310.027% mcap10.8% of flow
Common Stock
SEC:0001062993-22-001104:0·
€150,4371,944 shares@ €77.38550.039% mcap31.4% of flow
Common Stock
SEC:0001062993-21-012197·
€150,4371,944 shares@ €77.38550.039% mcap15.7% of flow
Common Stock
SEC:0001062993-21-012197:0·
025,700 shares0
Common Stock
SEC:0001062993-21-011498·
025,700 shares0
Common Stock
SEC:0001062993-21-011498:0·
€225,6334,516 shares@ €49.9630.058% mcap47.1% of flow
Common Stock
SEC:0001177648-21-000025·
€225,6334,516 shares@ €49.9630.058% mcap23.5% of flow
Common Stock
SEC:0001177648-21-000025:0·
9 of 9 declarations
About Luly Jay R.
Jay R. Luly is the Chief Executive Officer of Enanta Pharmaceuticals Inc. He is responsible for the strategic and operational direction of the company, which focuses on developing innovative medicines. Luly is committed to advancing Enanta's mission.
